


CLAIMS

- 1.) A compound of the formula



wherein the molecular weight of the compound of formula I is less than 1000 AMU;

- 5 X is $>\text{CH}_2$, $>\text{NH}$, sulfur, $>\text{S}=\text{O}$, $>\text{SO}_2$ or oxygen; wherein said $>\text{CH}_2$ and $>\text{NH}$ may optionally be substituted with a suitable substituent;

R¹ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl and other suitable substituents;

- 10 R² is selected from the group consisting of hydrogen, (C₁-C₆)alkyl and other suitable substituents;


s is an integer from 0-4;

R³ is R⁴, R⁵-(NR⁶)-, R⁵-S-, R⁵-(S=O)-, R⁵-(SO₂)-, R⁵-SO₂-NR⁶-, R⁵-(NR⁶)-SO₂-, R⁵-O-, R⁵-(C=O)-, R⁵-(NR⁶)-(C=O)-, R⁵-(C=O)-NR⁶-, R⁵-O-(C=O)-, R⁵-(C=O)-O-, R⁵-CR⁷=CR⁸- or R⁵-C≡C-; such that the molecular weight of R³ is less than 500 AMU;

- 15 R⁴, R⁵ and R⁶ are each selected from the group consisting of hydrogen, (C₁-C₆)alkyl and other suitable substituents;

wherein the molecular weight of the compound of formula I is less than 1000 AMU;
or a pharmaceutically acceptable salt thereof.

2. A compound of the formula



20

wherein R¹ is selected from the group of substituents consisting of hydrogen, $-\text{C}\equiv\text{N}$, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic and (R¹⁷)₂-N-; wherein each of the aforesaid (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl, phenyl, (C₁-C₁₀)heteroaryl and (C₁-C₁₀)heterocyclic substituents may

optionally be independently substituted by one to four moieties independently selected from the group consisting of halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₃-C₁₀)cycloalkyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, formyl, -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C₁-C₆)alkyl]-N-(C=O)-, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C₁-C₆)alkyl]-N-, H₂N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-NH-, [(C₁-C₆)alkyl]₂-N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, [(C₁-C₆)alkyl]₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-HN-(C=O)-NH-, (phenyl)₂-N-(C=O)-NH-, phenyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, (phenyl)₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-O-(C=O)-NH-, (C₁-C₆)alkyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-SO₂NH-, phenyl-SO₂NH-, (C₁-C₆)alkyl-SO₂-, phenyl-SO₂-, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₆)alkyl-(C=O)-O-, phenyl-(C=O)-O-, H₂N-(C=O)-O-, (C₁-C₆)alkyl-HN-(C=O)-O-, [(C₁-C₆)alkyl]₂-N-(C=O)-O-, phenyl-HN-(C=O)-O- and (phenyl)₂-N-(C=O)-O-; wherein when said R¹ phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of (C₁-C₆)alkyl, halo, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkyl and perhalo(C₁-C₆)alkoxy;

s is an integer from zero to four;

each R² is independently selected from the group consisting of hydrogen, halo, (C₁-C₄)alkyl, and -CF₃;

R³ is R⁴, R⁵-(NR⁶)-, R⁵-S-, R⁵-(S=O)-, R⁵-(SO₂)-, R⁵-SO₂-NR⁶-, R⁵-(NR⁶)-SO₂-, R⁵-O-, R⁵-(C=O)-, R⁵-(NR⁶)-(C=O)-, R⁵-(C=O)-NR⁶-, R⁵-O-(C=O)-, R⁵-(C=O)-O-, R⁵-CR⁷=CR⁸- or R⁵-C≡C-;

R⁴ is hydrogen, halo, -C≡N, (R⁹)_m-(C₁-C₆)alkyl, (R⁹)_m-(C₂-C₆)alkenyl, perhalo(C₁-C₆)alkyl, (R⁹)_m-phenyl, (R⁹)_m-(C₁-C₁₀)heteroaryl, (R⁹)_m-(C₁-C₁₀)heterocyclic, or (R⁹)_m-(C₃-C₁₀)cycloalkyl,

R⁵ is hydrogen, -C≡N, (R⁹)_m-(C₁-C₆)alkyl, (R⁹)_m-(C₂-C₆)alkenyl, (R⁹)_m-(C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, (R⁹)_m-phenyl, (R⁹)_m-(C₁-C₁₀)heteroaryl, (R⁹)_m-(C₁-C₁₀)heterocyclic, or (R⁹)_m-(C₃-C₁₀)cycloalkyl;

m is an integer from one to three;

R⁶ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, R¹³-(C=O)-, and R¹³-(SO₂)-; wherein each of the aforesaid (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl,

phenyl, (C₁-C₁₀)heteroaryl and (C₁-C₁₀)heterocyclic substituents may optionally be independently substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₃-C₁₀)cycloalkyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, formyl, -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C₁-C₆)alkyl]-N-(C=O)-, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C₁-C₆)alkyl]-N-, H₂N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-NH-, [(C₁-C₆)alkyl]₂-N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, [(C₁-C₆)alkyl]₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-HN-(C=O)-NH-, (phenyl)₂-N-(C=O)-NH-, phenyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, (phenyl)₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-O-(C=O)-NH-, (C₁-C₆)alkyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-SO₂NH-, phenyl-SO₂NH-, (C₁-C₆)alkyl-SO₂-, phenyl-SO₂-, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₆)alkyl-(C=O)-O-, phenyl-(C=O)-O-, H₂N-(C=O)-O-, (C₁-C₆)alkyl-HN-(C=O)-O-, [(C₁-C₆)alkyl]₂-N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl)₂-N-(C=O)-O-; wherein when said R⁶ phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of (C₁-C₆)alkyl, halo, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkyl and perhalo(C₁-C₆)alkoxy;

R⁷ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, and (C₃-C₁₀)cycloalkyl;

R⁸ is hydrogen, or (C₁-C₆)alkyl;

wherein when R⁹ is a substituent on a carbon atom each R⁹ is independently selected from the group consisting of hydrogen, halo, R¹¹-(C₁-C₆)alkyl, R¹¹-(C₂-C₆)alkenyl, R¹¹-(C₂-C₆)alkynyl, azido, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, R¹¹-[N(R¹⁰)]-SO₂-, -NO₂, (R¹¹)₂N-, R¹¹-SO₂-[N(R¹⁰)]-, R¹¹-(C=O)-[N(R¹⁰)]-, (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-, R¹¹-O-(C=O)-[N(R¹⁰)]-, -C≡N, R¹¹-(C=O)-, R¹¹-O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R¹¹-O-, perhalo(C₁-C₆)alkoxy, R¹¹-(C=O)-O-, R¹¹-O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-;

wherein when R⁹ is a substituent on a nitrogen atom each R⁹ is independently selected from the group consisting of hydrogen, R¹¹-(C₁-C₆)alkyl, R¹¹-(C₂-C₆)alkenyl, R¹¹-(C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkyl-SO₂-, R¹¹-[N(R¹⁰)]-SO₂-, R¹¹-(C=O)-, R¹¹-O-(C=O)- and (R¹¹)-[N(R¹⁰)]-(C=O)-;

R¹⁰ is hydrogen or (C₁-C₄)alkyl;

R¹¹ is selected from the group consisting of hydrogen, R¹²-(C₁-C₆)alkyl, (C₃-C₆)alkenyl, (C₃-C₆)alkynyl, (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl; wherein each of the aforesaid R¹²-(C₁-C₆)alkyl, (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, -C≡N, (C₁-C₆)alkyl, (C₁-C₆)alkyl-O-(C=O)-, and (C₁-C₆)alkoxy;

R¹² is selected from the group consisting of hydrogen, hydroxy, (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl; wherein each of the aforesaid (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, -C≡N, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy;

R¹³ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₁₀)heteroaryl-O-, (C₁-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, phenyl-(C=O)-NH-, and phenyl-(C=O)-[[(C₁-C₆)alkyl]-N]-;

X is >C(R¹⁴)₂, >NR¹⁵, sulfur, >S=O, >SO₂ or oxygen;

each R¹⁴ is independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₁₀)heteroaryl-O-, (C₁-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₁-C₁₀)heteroaryl-(C=O)-, (C₁-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[[(C₁-C₆)alkyl]-N]-(C=O)-, (C₁-C₁₀)heteroaryl-NH-(C=O)-, (C₁-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)- and (C₁-C₆)alkyl-(C=O)-O-; wherein two R¹⁴ substituents may be optionally taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring;

R¹⁵ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, R¹⁶-(C=O)-, and R¹⁶-(SO₂)-; wherein each of the aforesaid (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl,

phenyl, (C₁-C₁₀)heteroaryl and (C₁-C₁₀)heterocyclic substituents may optionally be independently substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₃-C₁₀)cycloalkyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, formyl, -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C₁-C₆)alkyl]-N-(C=O)-, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C₁-C₆)alkyl]-N-, H₂N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-NH-, [(C₁-C₆)alkyl]₂-N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, [(C₁-C₆)alkyl]₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-HN-(C=O)-NH-, (phenyl)₂-N-(C=O)-NH-, phenyl-HN-(C=O)-[(C₁-C₆)alkyl]-N-, (phenyl)₂-N-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-O-(C=O)-NH-, (C₁-C₆)alkyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(C₁-C₆)alkyl]-N-, (C₁-C₆)alkyl-SO₂NH-, phenyl-SO₂NH-, (C₁-C₆)alkyl-SO₂-, phenyl-SO₂-, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₆)alkyl-(C=O)-O-, phenyl-(C=O)-O-, H₂N-(C=O)-O-, (C₁-C₆)alkyl-HN-(C=O)-O-, [(C₁-C₆)alkyl]₂-N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl)₂-N-(C=O)-O-; wherein each of the aforesaid (C₁-C₁₀)heteroaryl and (C₁-C₁₀)heterocyclic substituents may optionally be independently substituted on any nitrogen atom by a substituent selected from the group consisting of (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₃-C₁₀)cycloalkyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, formyl, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C₁-C₆)alkyl]-N-(C=O)-, (C₁-C₆)alkyl-SO₂- and phenyl-SO₂-; wherein when said R¹⁵ phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of (C₁-C₆)alkyl, halo, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkyl and perhalo(C₁-C₆)alkoxy;

R¹⁶ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, (C₁-C₆)alkoxy and perhalo(C₁-C₆)alkoxy;

each R¹⁷ is independently selected from hydrogen, (C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic and (C₃-C₁₀)cycloalkyl; wherein each of the aforesaid R¹⁷ substituents (C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic and (C₃-C₁₀)cycloalkyl may optionally be substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C₁-C₆)alkyl,

- (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₁-C₁₀)heteroaryl-O-, (C₁-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₁-C₁₀)heteroaryl-(C=O)-, (C₁-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)- (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[[(C₁-C₆)alkyl]-N]-(C=O)-, (C₁-C₁₀)heteroaryl-NH-(C=O)-, (C₁-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-, (C₁-C₆)alkyl-(C=O)-O- and phenyl-(C=O)-O-; wherein each of the aforesaid R¹⁷ substituents (C₁-C₁₀)heteroaryl and (C₁-C₁₀)heterocyclic may optionally be substituted on any nitrogen atom by a moiety selected from the group consisting of (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl, (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₁-C₁₀)heteroaryl-(C=O)-, (C₁-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)- (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[[(C₁-C₆)alkyl]-N]-(C=O)-, (C₁-C₁₀)heteroaryl-NH-(C=O)-, (C₁-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-, (C₁-C₆)alkyl-(C=O)-O- and phenyl-(C=O)-O-; wherein two R¹⁷ (C₁-C₆)alkyl groups may be taken together with the nitrogen atom to which they are attached to form a five to six membered heterocyclic or heteroaryl ring;
- or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 2, wherein R³ is R⁴.
 4. A compound according to claim 3, wherein R⁴ is hydrogen, halo, -C≡N or perhalo(C₁-C₆)alkyl.
 5. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkyl.
 6. A compound according to claim 3, wherein R⁴ is (R⁹)_m-phenyl, (R⁹)_m-(C₁-C₁₀)heteroaryl, (R⁹)_m-(C₁-C₁₀)heterocyclic or (R⁹)_m-(C₃-C₁₀)cycloalkyl.
 7. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkyl; m is 1; R⁹ is selected from the group consisting of hydrogen, halo, R¹¹-(C₁-C₆)alkyl, R¹¹-(C₂-C₆)alkenyl, R¹¹-(C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, R¹¹-[N(R¹⁰)]-SO₂-, -NO₂, R¹¹-SO₂-[N(R¹⁰)]-, -C≡N, and perhalo(C₁-C₆)alkoxy.
 8. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkenyl; m is 1; R⁹ is selected from the group consisting of hydrogen, halo, R¹¹-(C₁-C₆)alkyl,

R^{11} -(C₂-C₆)alkenyl, R^{11} -(C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, R^{11} -[N(R¹⁰)]-SO₂-, -NO₂, R^{11} -SO₂-[N(R¹⁰)]-, -C≡N, and perhalo(C₁-C₆)alkoxy.

9. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkyl; m is 1; R⁹ is selected from the group consisting of (R¹¹)₂N-, R^{11} -(C=O)-[N(R¹⁰)]-,
5 (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-, R^{11} -O-(C=O)-[N(R¹⁰)]-, R^{11} -(C=O)-, R^{11} -O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R^{11} -O-, R^{11} -(C=O)-O-, R^{11} -O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-.

10. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkyl; m is 1; R⁹ is selected from the group consisting of (R¹¹)₂N-, R^{11} -(C=O)-[N(R¹⁰)]-, (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-, R^{11} -O-(C=O)-[N(R¹⁰)]-, R^{11} -(C=O)-, R^{11} -O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R^{11} -O-, R^{11} -(C=O)-O-, R^{11} -O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-;
10 and R¹¹ is selected from the group selected from hydrogen, R¹²-(C₁-C₆)alkyl, (C₃-C₆)alkenyl, and (C₃-C₆)alkynyl.

11. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁-C₆)alkyl; m is 1; R⁹ is selected from the group consisting of R^{11} -(C=O)-[N(R¹⁰)]-, (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-,
15 R^{11} -O-(C=O)-[N(R¹⁰)]-, R^{11} -(C=O)-, R^{11} -O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R^{11} -O-, R^{11} -(C=O)-O-, R^{11} -O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-; and R¹¹ is selected from the group selected from (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl; wherein each of the aforesaid (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently
20 selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

12. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁)alkyl; m is 1; R⁹ is selected from the group consisting of hydrogen, halo, R^{11} -(C₁-C₆)alkyl, R^{11} -(C₂-C₆)alkenyl, R^{11} -(C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, R^{11} -[N(R¹⁰)]-SO₂-, -NO₂, R^{11} -SO₂-[N(R¹⁰)]-, -C≡N, and perhalo(C₁-C₆)alkoxy; and R¹¹ is selected from the group
25 consisting of (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl; wherein each of the aforesaid (C₁-C₁₀)heterocyclic, (C₁-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

13. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁)alkyl; m is 1; R⁹ is selected from the group consisting of (R¹¹)₂N-, R^{11} -(C=O)-[N(R¹⁰)]-, (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-, R^{11} -O-(C=O)-[N(R¹⁰)]-, R^{11} -(C=O)-, R^{11} -O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R^{11} -O-, R^{11} -(C=O)-O-, R^{11} -O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-;
30 and R¹¹ is hydrogen, R¹²-(C₁-C₆)alkyl, (C₃-C₆)alkenyl, and (C₃-C₆)alkynyl.

14. A compound according to claim 3, wherein R⁴ is (R⁹)_m-(C₁)alkyl; m is 1; R⁹ is selected from the group consisting of (R¹¹)₂N-, R^{11} -(C=O)-[N(R¹⁰)]-, (R¹¹)-[N(R¹⁰)]-(C=O)-[N(R¹⁰)]-, R^{11} -O-(C=O)-[N(R¹⁰)]-, R^{11} -(C=O)-, R^{11} -O-(C=O)-, (R¹¹)-[N(R¹⁰)]-(C=O)-, R^{11} -O-, R^{11} -(C=O)-O-, R^{11} -O-(C=O)-O- and (R¹¹)-[N(R¹⁰)]-(C=O)-O-;
35

and R^{11} is selected from the group selected from (C_1-C_{10}) heterocyclic, (C_1-C_{10}) heteroaryl, (C_3-C_{10}) cycloalkyl, and phenyl; wherein each of the aforesaid (C_1-C_{10}) heterocyclic, (C_1-C_{10}) heteroaryl, (C_3-C_{10}) cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6) alkyl, and (C_1-C_6) alkoxy.

5 15. A compound according to claim 3, wherein R^4 is $(R^9)_m-(C_1)$ alkyl; m is 1; R^9 is selected from the group consisting of $R^{11}-(C=O)-[N(R^{10})]-$, $(R^{11})-[N(R^{10})]-(C=O)-[N(R^{10})]-$, $R^{11}-O-(C=O)-[N(R^{10})]-$, $R^{11}-(C=O)-$, $R^{11}-O-(C=O)-$, $(R^{11})-[N(R^{10})]-(C=O)-$, $R^{11}-O-$, $R^{11}-(C=O)-O-$, $R^{11}-O-(C=O)-O-$ and $(R^{11})-[N(R^{10})]-(C=O)-O-$; and R^{11} is selected from the group consisting of hydrogen, $R^{12}-(C_1-C_6)$ alkyl and (C_1-C_{10}) heteroaryl; wherein each of the
10 aforesaid (C_1-C_6) alkyl and (C_1-C_{10}) heteroaryl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6) alkyl, and (C_1-C_6) alkoxy.

16. A compound according to any of the previous claims wherein X is $>C(R^{14})_2$.

17. A compound according to claims 1-15 wherein X is $>NR^{15}$.

18. A compound according to claims 1-15 wherein X is $-S-$

15 19. A compound according to claims 1-15 wherein X is $>S=O$.

20. A compound according to claims 1-15 wherein X is $>SO_2$.

21. A compound according to claims 1-15 wherein X is $-O-$.

22. A compound according to any of the previous claims wherein R^1 is optionally substituted (C_1-C_6) alkyl, phenyl, (C_3-C_{10}) cycloalkyl, (C_1-C_{10}) heteroaryl or (C_1-C_{10}) heterocyclic.

20 23. A compound according to claims 1-21 wherein R^1 is (C_1-C_6) alkyl, optionally substituted with one to four groups independently selected from halo, hydroxy, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, perhalo (C_1-C_6) alkyl, perhalo (C_1-C_6) alkoxy, $-C\equiv N$, $-NO_2$, amino, (C_1-C_6) alkylamino, $[(C_1-C_6)alkyl]_2$ -amino, $HO-(C=O)-$, $(C_1-C_6)alkyl-(C=O)-$, $(C_1-C_6)alkyl-O-(C=O)-$, $(C_1-C_6)alkyl-CO_2-$, $(C_1-C_6)alkyl-(C=O)-NH-$, $(C_1-C_6)alkyl-NH-(C=O)-$,
25 $(C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-$, $(C_1-C_6)alkyl-[((C_1-C_6)alkyl)-N]-(C=O)-$, $(C_1-C_6)alkyl-SO_2NH-$, $(C_1-C_6)alkyl-SO_2-$, optionally substituted phenyl- $(C=O)-$, optionally substituted phenyl- $(C=O)-O-$, optionally substituted phenoxy, optionally substituted phenyl- $NH-(C=O)-$, optionally substituted phenyl- $[((C_1-C_6)alkyl)-N]-(C=O)-$, optionally substituted phenyl- $(C=O)-NH-$ and optionally substituted phenyl- $(C=O)-[((C_1-C_6)alkyl)-N]-$.

30 24. A compound according to claims 1-21 wherein R^1 is (C_1-C_4) alkyl.

25. A compound according to claims 1-21 wherein R^1 is optionally substituted (C_3-C_6) cycloalkyl.

26. A compound according to claims 1-21 wherein R^1 is optionally substituted phenyl.

35 27. A compound according to claims 1-21 wherein R^1 is optionally substituted phenyl wherein said substituents are independently selected from the group consisting of halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, perhalo (C_1-C_6) alkyl, $-C\equiv N$, $(C_1-C_6)alkyl-(C=O)-$, $HO-(C=O)-$,

(C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, amino,
 (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-(C=O)-NH-,
 (C₁-C₆)alkyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, H₂N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-NH-,
 [(C₁-C₆)alkyl]₂-N-(C=O)-NH-, (C₁-C₆)alkyl-HN-(C=O)-[[(C₁-C₆)alkyl]-N]-,
 5 [(C₁-C₆)alkyl]₂-N-(C=O)-[[(C₁-C₆)alkyl]-N]-, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy,
 (C₁-C₆)alkyl-(C=O)-O-, H₂N-(C=O)-O-, (C₁-C₆)alkyl-HN-(C=O)-O- and
 [(C₁-C₆)alkyl]₂-N-(C=O)-O-.

28. A compound according to claim 26 wherein R¹ is optionally substituted phenyl
 containing two adjacent substituents which taken together with the carbon atoms to which
 10 they are attached form a five to six membered carbocyclic or heterocyclic ring.

29. A compound according to claims 1-21 wherein R¹ is (R¹⁷)₂-N-, wherein each
 R¹⁷ is independently selected from hydrogen, (C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heterocyclic and
 (C₃-C₁₀)cycloalkyl; wherein each of the aforesaid R¹⁷, (C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl,
 (C₁-C₁₀)heterocyclic and (C₃-C₁₀)cycloalkyl substituents may optionally be substituted by one
 15 to four moieties independently selected from the group consisting of halo, (C₁-C₆)alkyl,
 (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₁-C₁₀)heteroaryl,
 (C₁-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy,
 phenoxy, (C₁-C₁₀)heteroaryl-O-, (C₁-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-,
 (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, -NO₂, amino, (C₁-C₆)alkylamino,
 20 [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, (C₁-C₆)alkyl-(C=O)-NH-,
 (C₁-C₆)alkyl-(C=O)-[[(C₁-C₆)alkyl]-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[[(C₁-C₆)alkyl]-N]-,
 -C≡N, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₁-C₁₀)heteroaryl-(C=O)-,
 (C₁-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-,
 H₂N(C=O)- (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-,
 25 phenyl-[[(C₁-C₆)alkyl]-N]-(C=O)-, (C₁-C₁₀)heteroaryl-NH-(C=O)-,
 (C₁-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-, (C₁-C₆)alkyl-(C=O)-O- and
 phenyl-(C=O)-O-; wherein two R² (C₁-C₆)alkyl groups may be taken together with the nitrogen
 atom to form a five to six membered heterocyclic or heteroaryl ring;

30. A compound according to claim 29 wherein R¹ is (R¹⁷)₂-N- and wherein each
 30 R¹⁷ is independently selected from hydrogen, (C₁-C₄)alkyl, phenyl and (C₁-C₁₀)heterocyclic.

31. A compound according to claim 29 wherein R¹ is (R¹⁷)₂-N- and wherein two
 R² (C₁-C₆)alkyl groups may be taken together with the nitrogen atom to form a five to six
 membered heterocyclic or heteroaryl ring.

32. A compound according to any of the previous claims, wherein s is an integer
 35 from one to four and each R² is independently selected from the group consisting of halo,
 -C≡N, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl and perhalo(C₁-C₆)alkyl.

33. A compound according to claims 1-31, wherein s is an integer from one to four and zero, one or two of R² are independently selected from the group consisting of halo, (C₁-C₆)alkyl, perhalo(C₁-C₆)alkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, -C≡N, and H₂N(C=O)-.

5 34. A compound according to claims 1-31, wherein s is an integer from one to three and each R² is independently selected from the group consisting of halo, (C₁-C₆)alkyl, perhalo(C₁-C₆)alkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, -NO₂, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, -C≡N, and H₂N(C=O)-.

10 35. A compound according to claims 1-31, wherein s is an integer from one to two and each R² is independently selected from the group consisting of halo, (C₁-C₆)alkyl, perhalo(C₁-C₆)alkyl, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy and -C≡N.

36. A compound according to claim 35, wherein s is an integer from one to three and each R² is independently selected from the group consisting of fluoro, chloro and methyl.

15 37. A compound according to claim 2, wherein said compound is selected from the group consisting of:

1-Ethyl-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

20 [2-(3-Isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]- carbamic acid ethyl ester;

1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 2-(3-tert-butyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

25 1-(5-tert-Butyl-isoxazol-3-yl)-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 5-fluoro-2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

30 Ethyl-carbamic acid 2-fluoro-6-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

N-Ethyl-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acrylamide;

38. A method of treating an ERK/MAP kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to any of the previous claims.

35 39. A method of treating a p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to any of the previous claims.

40. A method for treating a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative
5 sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, ischemic necrosis, myocardial infarct, stroke burns, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel
10 disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising administering to said mammal an amount of a compound according to any of the previous claims, effective in treating such a condition.

41. A pharmaceutical composition for the treatment of a condition selected from the
15 group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic
20 pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a
25 human, comprising an amount of a compound according to any of the previous claims effective in such treatment and a pharmaceutically acceptable carrier.

42. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of ERK/MAP kinase in a mammal, including a human, comprising an amount of a compound according to any of the previous claims effective in such treatment
30 and a pharmaceutically acceptable carrier.

43. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of p38 kinase in a mammal, including a human, comprising an amount of a compound according to any of the previous claims effective in such treatment and a pharmaceutically acceptable carrier.